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The evidence-basis based on existing myopia control trials along with the supporting academic
literature were reviewed; this informed recommendations on the outcomes suggested from
clinical trials aimed at slowing myopia progression to show the effectiveness of treatments and
the impact on patients. These outcomes were classified as primary (refractive error and/or axial
length), secondary (patient reported outcomes and treatment compliance), and exploratory
(peripheral refraction, accommodative changes, ocular alignment, pupil size, outdoor activity/
lighting levels, anterior and posterior segment imaging, and tissue biomechanics). The currently
available instrumentation, which the literature has shown to best achieve the primary and
secondary outcomes, was reviewed and critiqued. Issues relating to study design and patient
selection were also identified. These findings and consensus from the International Myopia
Institute members led to final recommendations to inform future instrumentation development
and to guide clinical trial protocols.
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1. INTRODUCTION, SCOPE, AND GUIDING PRINCIPLES
This report has identified the primary, secondary, andexploratory outcomes suggested from clinical trials for
slowing myopia progression, showing the effectiveness of
treatments and the impact on patients. Currently available
instrumentation that the literature has shown to be the best to
achieve the primary and secondary outcomes was reviewed
and critiqued. Issues were also identified relating to study
design and patient selection in adherence to the tenets of the
Declaration of Helsinki and ethics. These findings and
consensus from the International Myopia Institute members
led to final recommendations to inform future instrumentation
development and guide clinical trial protocols.
2. STUDY DESIGN
When conducting a study to determine the efficacy of a
treatment for myopia control, it is critical to utilize sound
clinical trial methodology. Decisions when designing a stan-
dardized clinical trial not only minimize variability and bias,
they also maximize generalizability and allow for easier
comparison among studies. There are many decisions to be
made when designing a clinical trial.
2.1 Study Length
The average age of myopia onset in the United States and
Singapore is eight years of age, and the average age at which
myopia progression is reported to cease is roughly 16 years,
although progression at slower rates can also be observed in
children older than 16 years.1–3 However, age of myopia onset,
rate of progression, and duration of progression vary interna-
tionally, with Asians having earlier onset, faster rates of
progression, and longer duration of progression than other
races.4,5 Because myopia control interventions will be applied
for multiple years throughout the time myopia is progressing, it
is important that clinical trials evaluate efficacy over a long
period to ensure continued efficacy beyond any initial
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treatment effect.6 The Correction of Myopia Evaluation Trial
(COMET) demonstrates this point well. This large, well-
conducted clinical trial evaluating the efficacy of Progressive
Addition Lens spectacles versus standard spectacles, found a
treatment effect after 1 year; however, the treatment effect did
not continue to accumulate over the 2 subsequent years of the
trial.7 Evidence of diminishing efficacy beyond the first year
was also noted in other bifocal and Progressive Addition Lens
spectacle studies8,9 and orthokeratology (OK) studies.10
As demonstrated, the extrapolation of a 1-year treatment
effect to multiple years can lead to incorrect conclusions. To
employ the best evidence-based practice, it is important that
eye care providers have clinical trial research to support the
multi-year use of a particular treatment. If a treatment is shown
to provide an effect only over a short time period, this is also
valuable information that can allow a practitioner to make an
informed decision regarding when to change treatment
modalities. The length of the trial must also be balanced with
feasibility; as trial length increases, the ability to retain
participants becomes more difficult, progression begins to
slow naturally, and costs increase. For this reason, 3 years is the
recommended minimum length of a clinical trial assessing the
efficacy of a treatment for myopia control.
2.2 Participant Selection Criteria
This section is informed by 24 recent evidence-based papers
from four categories of clinical trials. Category 1 included
multifocal spectacles9,11–14 and under-correction with single
vision spectacles.15,16 Category 2 included OK lens trials.17–20
Category 3 included bifocal contact lenses6,21–23 and multifocal
contact lenses.24–28 Category 4 included atropine treat-
ment.29–32 Studies on outdoor activities were not included
because the cohorts were substantially different from those in
the other four categories.
2.2.1 Refractive Error.
2.2.1.1 Spherical or Spherical Equivalent Refractive Error.
Spherical refractive error was part of the inclusion criteria in
categories 2 and 3, whereas spherical equivalent refractive
error was mostly adopted in categories 1 and 4. Because the
amount of astigmatism was limited in each trial (see Section
2.2.1.4) and the value typically is no greater than 1.50 D, the
choice of whether to use spherical or spherical equivalent for
the inclusion criteria was generally inconsequential. For the
evaluation of myopia progression, spherical equivalent refrac-
tive error was adopted in all studies except OK studies. The
use of cycloplegia is discussed in Section 2.6 and refractive
error determination in Section 3.1.2.
2.2.1.2 Progression Over Period Prior to Enrollment. Four
trials adopted a minimum progression rate prior to enrollment
as an inclusion criteria.
One trial adopted one 0.3 D/year,26 one 0.5 D/year,33 one
1.0 D/year,31 and one 0.5 D progression since the last visit.21
Only the latter study reported that progression was assessed
‘‘based on clinical records, results of spectacle neutralization,
or written prescriptions.’’21 The criteria were adopted in
recent trials to confirm the prevention effect among partici-
pants who have at least a minimum level of recent myopia
progression. However, deciding progression on the basis of
typically two ‘‘noisy’’ data points could lead to errors in
participant selection, whereas recruiting non-progressing
myopes could cause overestimation (if in the treatment group)
or underestimation (if in the control group) of the treatment
effect and may be considered unethical.
2.2.1.3 Astigmatism Limit. An equal number of studies
adopted a maximum of 1.00 D or 1.50 D (n ¼ 10 each) with
two adopting 1.25 D (Table 1).
2.2.1.4 Anisometropia. Most studies (n¼ 8) have adopted a
maximum permissible limit of 1.50 D, but others have selected
1.00 D (n¼5), 1.25 D (n¼1), or 2.00 D (n¼2) (Table 1).
2.2.2 Age. While one study adopted a minimum age of 5
years, most adopted a minimum of 6 years of age. Most trials
adopted 12 years as the maximum age (n ¼ 6), but others
ranged from 7 years (n¼ 2) to 18 years (n¼ 2). There appears
to be no particular trend within inclusion criteria for the
modality of intervention (Table 1).
2.2.3 Previous Optical Correction. Previous optical
correction may affect the efficacy of a myopia control
intervention. Generally, spectacles and monofocal soft contact
lens (SCL) are accepted as options for previous correction;
however, in an under-correction spectacle study,16 participants
were excluded who had worn an under-corrected spectacle
prescription previously (i.e., had not been prescribed their full
myopic refractive correction). Rigid contact lens wearers were
specifically excluded, mostly in studies involving multifocal or
bifocal (SCL) and OK studies.
2.2.4 Previous Myopia Treatment. Patients with a history
of previous myopia control treatment were excluded in all
studies.
2.2.5 Exclusion Criteria. Participants with ocular pathol-
ogy, such as retinal detachment, were excluded in all studies,
as were patients with strabismus. Studies generally exclude
participants who are on medications that may affect pupil size,
accommodation, or have an impact on the ocular surface (such
as allergy medications). The literature does not always outline
specific exclusion criteria other than prescription range.
Systemic disease that may affect vision, vision development,
or contact lens wear (such as diabetes and Down syndrome),
were explicitly excluded in a recent study (Table 2).28
2.3 Appropriate Control Group
A placebo-controlled clinical trial in which participants do not
know their group assignment is generally considered the gold
standard. Ideally, the control or sham (placebo) treatment
cannot be distinguished from the active treatment with the
only difference between the treatment and control being a
hypothesized intervention, such as an optical design or active
pharmaceutical agent.35,36 That said, the most appropriate
control group will depend on the intervention being studied.
Studies with no control group are unable to demonstrate
treatment efficacy; for example, the rate of myopia progression
decreases naturally with age, so it is not possible to distinguish
between naturally declining progression and reduced progres-
sion attributable to the treatment, without a simultaneously
conducted control group.1,4 Likewise, studies utilizing histor-
ical control groups also allow the introduction of unknown
sources of bias. In several studies, historical control groups
have been used (Table 3). An appropriate control group
manages potential sources of bias, alleviating many of these
concerns. Treatment and control groups ideally should be
matched for factors such as age, starting refractive error, time
outdoors, ethnicity, and parental myopia status since these
factors are all known to influence progression rate. It is often a
challenge to keep participants in a control group, particularly if
the efficacy of the treatment group becomes or is perceived to
be established.
2.3.1 Pharmaceutical Studies. The recommended place-
bo is the vehicle used in the active treatment intervention but
without the active pharmaceutical agent being evaluated in the
treatment group. By using a control that differs from the
treatment drug’s active ingredient, any effect can be isolated to
the specific molecule being evaluated. When this is not
possible, the control treatment should mirror the active
treatment medication as closely as possible. In either case,
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the administration regimen should be the same whether a
participant is in a treatment or control group. In atropine
studies, past studies have applied a vehicle placebo to the
control group (Table 3).
2.3.2 Contact Lens Studies. The best choice for a control
group depends on the treatment modality being evaluated.
One prominent theory of myopia control hypothesizes that
peripheral myopic defocus slows progression.4 Both single
vision spectacles and spherical SCL change peripheral defocus
from the uncorrected state by amounts that vary between lens
designs and by lens power.37–39 A control contact lens made of
the same material is ideal and, if possible, the optics of the
control lens should not change peripheral defocus. However,
current options change the peripheral refraction and spherical
aberration40,41 so, ideally, the ‘‘optimal’’ lens may be one with
known levels of spherical aberration that do not vary with lens
power. In multifocal or bifocal SCL studies, control groups have
generally used single-vision SCL (Table 3). Two randomized
controlled trials have shown no clinically meaningful differ-
ence in myopia progression between single vision contact
lenses and single vision spectacles.42,43 However, such studies
do not allow participant masking.
2.2.3 OK Studies. There is no ideal control group that
allows double masking. Spherical gas permeable contact
lenses, SCL, or spectacles must be worn during the day to
correct vision, unlike OK lenses where the child typically
TABLE 1. Selection Criteria in Recent Myopia Control Clinical Trials
Author, Year Intervention
SER, Min to
Max (D)
Cyclo-
plegia
Ast
Limit (D)
Aniso
Limit (D)
VA
Min
Age, Min
to Max (y)
Gwiazda et al., 200212 Spectacle (multifocal) 4.50 to 1.25 Y 1.50 1.00 20/32 6 to 11
Edwards et al., 200211 Spectacle (multifocal) 4.50 to 1.25 Y 1.50 1.50 20/20 7 to 10.5
Hasebe et al., 200813 Spectacle (multifocal) 6.00 to 1.25 N 1.50 1.50 20/20 6 to 12
COMET group* 20119 Spectacle (multifocal) 0.75 to 2.50 and
esophoria ‡2 PD @ 33
cm
Y 1.50 1.00 20/20 8 to <12
Berntsen et al., 201234 Spectacle (progressive
addition lens)
4.50 to 0.75 in each
meridian with esophoria
if more myopic than
2.25 SER
Y 2.00 2.00 20/30 6 to 11
Hasebe et al., 201414 Spectacle (multifocal) 4.50 to 0.50 Y 1.50 1.50 20/30 6 to 12
Adler et al., 200615 Spectacle (under corr.) 6.00 to 0.50 N 1.50 1.50 20/30 (6/9) 6 to 15
Sun et al., 201716 Spectacle (under corr.) 6.00 to 0.50 Y 1.50 1.00 20/20 12 (grade 7)
Kakita et al., 201118 Orthokeratology 10.0 to 0.50 N 1.50 1.50 20/20 8 to 16
Walline et al., 200917 Orthokeratology 4.00 to 0.75 Y 1.00 — 20/20 8 to 11
Cho et al., 201219 Orthokeratology 4.50 to 0.50 N 1.25 1.50 20/20 6 to 10
Santodomingo-Rubido et
al., 201220
Orthokeratology 4.00 to 0.75 Y 1.00 — 20/20 6 to 12
Lam et al., 201422 SCL (concentric bifocal) 5.00 to 1.00 Y 1.00 1.25 20/20 8 to 12
Aller et al., 201621 SCL (concentric bifocal) 6.00 to 0.50 Y 1.00 2.00 20/20 8 to 18
Pomeda et al., 201723 SCL (concentric bifocal) 4.00 to 0.75 Y 1.00 1.00 20/25 8 to 12
Chamberlain et al., 20176 SCL (concentric bifocal) 4.00 to 0.75 Y 1.00 1.00 20/25 8 to 12
Walline et al., 201324 SCL (multifocal) 6.00 to 1.00 Y 1.00 1.00 20/20 8 to 11
Fujikado et al., 201425 SCL (multifocal) 3.50 to 1.00 Y 1.00 1.00 20/20 10 to 16
Paune et al., 201526 SCL (multifocal) 7.00 to 0.75 Y 1.25 1.00 20/20 9 to 16
Cheng et al., 201627 SCL (multifocal) 4.00 to 0.75 Y 1.00 1.00 20/25 8 to 11
Walline et al., 201728 SCL (multifocal) 5.00 to 0.75 Y 1.00 2.00 20/25 7 to 11
Chua et al., 200629 Atropine (1.00%) 6.00 to 1.00 Y 1.50 1.50 20/32 6 to 12
Chia et al., 201230 Atropine (0.01%) < 2.00 Y 1.50 NR 20/32 6 to 12
Polling et al., 201631 Atropine (0.50%)  3.00 Y NR NR NR 5 to 10
Wang et al., 201732 Atropine (0.50%) 2.00 to 0.50 Y NR NR NR 8 to 11
under corr., under correction; SER, spherical equivalent refractive error; AST, astigmatism; ANISO, anisometropia; VA, visual acuity; PD, prism
dioptres; NR, not reported; D, dioptre; y, years.
* The correction of myopia evaluation trial.
TABLE 2. Typical Inclusion/Exclusion Criteria, Although Should Be
Altered to Address Specific Study Hypothesis
Selection Criteria
Refractive error
Cyclopleged spherical or Spherical Equivalent myopia of at least
0.75 D
Astigmatism 1.00 D
Anisometropia 1.50 D
Age
6–12 years
Visual acuity
20/20 minimum
Exclusion Criteria
Previous RGP wear
History of previous myopia control treatment
Ocular pathology
Binocular vision anomaly
Medications that may affect pupil size, accommodation or have an
impact on ocular surface
Systemic disease that may affect vision, vision development or the
treatment modality
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wears the contact lens at night and needs no correction during
the day to see clearly after removal. Alignment fitted gas
permeable contact lenses can flatten the cornea and thus
contaminate the apparent influence of the lens on refractive
error.44 For these reasons, spectacle lenses are adequate
control lenses. There is also evidence that spherical surfaced
SCL do not alter myopia progression, making them a viable
option as well42; however, even these lenses (brand identified
by personal communication with the principal investigator)
had levels of spherical aberration that varied with lens power
(minus lenses inducing negative spherical aberration). There-
fore, presumably, the optics of the lenses change peripheral
defocus, so not every person evaluated had ‘‘the same’’
control. In previous multifocal spectacle studies, control
groups generally used single vision spectacle lenses (Table 3).
2.3.4 Multifocal Spectacle Studies. Control groups
generally used single-vision spectacle lenses. It is not possible
to mask bifocal spectacle lenses.
2.4 Randomization and Stratification
Randomization is a critical part of a clinical trial that distributes
potential confounding baseline characteristics (both known
and unknown) between the treatment groups and the control
group.35,36 Randomization assignments should not be available
to investigators in advance and should be accessible only after
the investigator has confirmed the participant’s eligibility to be
enrolled in the clinical trial; this is best administered using an
online portal that requires key eligibility checks prior to
revealing the randomization assignment.
Stratifying randomization by key factors known to influence
myopia progression—such as age and race/ethnicity—should
be considered. Stratification should be limited to a few key
factors. To avoid detrimental effects from over-stratifying, a
statistician should always be consulted during the planning
stage of any study to determine how many stratification factors
can be considered based on the planned size of the study. To
help ensure more equal allocation of important stratification
factors between the treatment and control group, block
randomization using random, even, small block sizes should
be employed. Randomization schemes should be generated
using appropriate statistical software.
An intent-to-treat philosophy should be used when analyz-
ing data. Once a participant is randomized to a particular
group, that participant should always be analyzed as part of the
assigned treatment group, even if the participant later
discontinues treatment or changes treatment groups during
the study. The intent-to-treat principle preserves randomization
and prevents the introduction of bias during analyses. A per-
protocol population is a subset of the intent-to-treat population
who completed the study in accordance with the protocol.
Users of this intent-to-treat philosophy should be aware that
treatment effects might be conservative (e.g., due to noncom-
pliance), and interpretation of endpoints might be difficult if
large numbers of participants change over to the opposite
treatment arm.
In most previous studies, randomized controlled trials were
adopted. Three studies using OK did not use randomiza-
tion.17,18,20 These studies had inclusion criteria, but partici-
pants and their parents had the choice between OK or single
vision spectacles. Several studies were stratified by age or
refraction (Table 2).
2.5 Masking
Clinical trials should utilize double masking whenever possible
to minimize the potential for bias (i.e., both the participant and
the examiner collecting primary outcome data should be
masked to the participant’s treatment assignment). Masking of
the participant helps ensure they remain compliant with their
assigned treatment and do not change their behavior in a way
that might influence the outcome. In the case of OK,
participant masking is not possible (see Section 2.3). At a
minimum, investigators who assess study outcomes should
TABLE 3. Control Group, Randomization, and Masking
Author, Year Intervention Control Randomization Stratification Masking
Gwiazda et al., 20037 Spectacle (multifocal) Spectacle (SV) Y N Y
Hasebe et al., 200813 Spectacle (multifocal) Spectacle (SV) Y N Y
Edwards et al., 200211 Spectacle (multifocal) Spectacle (SV) Y N Y
Berntsen et al., 201234 Spectacle (Progressive Addition Lens) Spectacle (SV) Y Y Y
Hasebe et al., 201414 Spectacle (multifocal) Spectacle (SV) Y N Y
Adler et al., 200615 Spectacle (under corr.) Spectacle (SV) Y N N
Sun et al., 201716 Spectacle (under corr.) Spectacle (SV) N N N
Cho et al., 201219 OK Spectacle (SV) Y N N
Kakita et al., 201118 OK Spectacle (SV) N N N
Santodomingo-Rubido et al., 201220 OK Spectacle (SV) N N N
Walline et al., 200917 OK Historical (SV SCL) N N N
Pomeda et al., 201723 SCL (concentric bifocal) Spectacle (SV) Y Y N
Chamberlain et al., 20176 SCL (concentric bifocal) SCL Y Y Y
Aller et al., 201621 SCL (concentric bifocal) SCL (SV) Y Y Y
Lam et al., 201422 SCL (concentric bifocal) SCL (SV) Y N Y
Walline et al., 201728 SCL (Multifocal) SCL (SV) Y Y Y
Cheng et al., 201627 SCL (Multifocal) SCL (SV) Y Y Y
Fujikado et al., 201425 SCL (Multifocal) SCL (SV) Y Y N
Walline et al., 201324 SCL (Multifocal) Historical (SV SCL) N N N
Paune et al., 201526 SCL (Multifocal) SCL (SV) N N N
Wang et al., 201732 Atropine (0.50%) Placebo Y Y Y
Polling et al., 201631 Atropine (0.50%) None N N N
Chua et al., 200629 Atropine (1.00%) Placebo Y N Y
Chia et al., 201230 Atropine (0.01%) Historical (Placebo) Y N N
SV, single vision; under corr, under correction; OK, orthokeratology; SCL, soft contact lens; Y, yes; N, no.
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always be masked to minimize the introduction of unintended
bias by the investigator during the study due to consciously or
subconsciously treating participants differently.35,36
In the previous studies for spectacle, SCL, and atropine,
masking was usually employed. In OK studies, masking could
not be adopted as the control group used spectacles. However,
examiners who were masked with regard to the lens
assignments performed portions of the clinical examinations,
including refraction, axial length measurement, and prescrib-
ing spectacles. An unmasked investigator performed allocation
using a random number table or a computer software program
that generated a random sequence.
2.6 Cycloplegia
Cycloplegia should be used when measuring primary out-
comes in studies of myopia progression to minimize variability.
The recommended regimen that has been used in multiple
clinical trials is two drops of 1% tropicamide separated by 5
minutes with primary outcome measures commencing 30
minutes after the first drop of tropicamide is instilled. This
protocol has been previously evaluated by Manny and
colleagues45 in an ethnically diverse cohort of children
enrolled in the Correction of Myopia Evaluation Trial (COMET)
and determined to be an appropriate method for cycloplegia.
Residual accommodation was found to be small (0.38 6 0.41
D). Work comparing the effects of cyclopentolate and
tropicamide also found no meaningful difference in measured
refractive error between agents 30 minutes after instillation.46
Given the unnecessarily longer-lasting cycloplegic and mydri-
atic effects of cyclopentolate versus 1% tropicamide as well as
minimal additional gain in cycloplegia with cyclopentolate in
myopic children, 1% tropicamide is recommended in optical
treatment studies. If used consistently throughout the study,
1% tropicamide provides adequate cycloplegia for outcome
measures while balancing the importance of retaining children
in longitudinal clinical trials, thereby minimizing the duration
of mydriasis and cycloplegia upon completion of each study
visit. As atropine also causes cycloplegia, the use of a
cycloplegic agent for refraction with less potency could
confound the assessment of the treatment effect. In studies
involving pharmaceutical interventions, the baseline refractive
error and biometry measurements used to calculate the change
in myopia progression and axial growth should be performed
shortly after the child has begun treatment using their assigned
intervention so that the baseline also has the combined effect
of the cycloplegics.
2.7 Assessment of Rebound
The question of rebound after ceasing treatment is important
to consider for any myopia control treatment. For a treatment
to be beneficial, the effect must be maintained after treatment
is stopped. Studies of atropine demonstrate a rebound
(accelerated eye growth) after discontinuing use and is greatest
with higher concentrations of atropine.47 While studies
utilizing multifocal spectacles and SCL have not produced
evidence of a rebound,34 it is possible that more efficacious
optical treatments might be prone to more accelerated eye
growth after discontinuation of treatment.
In studies aimed to evaluate the potential presence of
accelerated progression after ceasing treatment, the minimum
recommended time period over which a rebound effect should
be evaluated is 1 year due to naturally occurring seasonal
variations in myopia progression (slower growth in the
summer versus the winter).48 Assessing for a rebound effect
is best accomplished in a clinical trial in which children
assigned to the treatment group are switched to the control
treatment, with all children in the trial then followed using the
control treatment. However, ethical implications of this
approach should be considered.
2.8 Safety
2.8.1 Standardized Adverse Event Reporting. With any
new or developing medical technology, it is important to
continuously evaluate the cost versus benefit of the technol-
ogy. For example, for children wearing SCLs, it should be
considered whether the benefits provided by the contact lens
(such as in correcting vision or controlling myopia progres-
sion) outweigh any ocular health risks.
Thirty collaborating centers of the World Health Organiza-
tion49 have established common definitions of terms related to
adverse event reporting. Specifically, an adverse event is ‘‘any
untoward medical occurrence in a patient or clinical investi-
gation participant’’ administered a drug or device, which ‘‘does
not have to have a causal relationship.’’ Therefore, an adverse
event can ‘‘be any unfavorable and unintended sign,’’ symptom
or disease associated with the use of a medical device or
drug.50 It is necessary to make a risk-benefit judgment for
approval or use of a product; to do this effectively, the
classification and reporting of adverse events should occur in a
standardized manner and timeframe. If occurring within a
study, this event information must also be communicated to
the manufacturer, care provider, patient constituencies, and
institutional review board.
Contact lens adverse events can be classified in several
ways, such as graphically represented by a decision tree.51
Specifically, an adverse event should first be classified as either
‘‘serious’’ or ‘‘non-serious.’’ Serious events are those that are
life threatening, require inpatient or prolonged hospitalization,
or may cause permanent impairment or damage. An important
serious adverse event related to the eye and contact lens use is
the occurrence of microbial keratitis. Non-serious events may
include red eye and discomfort (see Section 2.8.2). Adverse
events are often further subdivided in terms of severity (such
as mild, moderate, or severe), device-related (often referred to
as a ‘‘device effect’’), and whether it was unanticipated versus
anticipated (often referred to as ‘‘not unanticipated’’ because
anticipated suggests that an unfavorable occurrence is likely to
occur). Specifically, adverse events at all times should be
differentiated from normal or anticipated consequences of
contact lens use, such as minor eye dryness52 and changes in
corneal morphology.53–55
Many governmental organizations around the globe protect
consumers by creating device reporting methods. For example,
in the United States, the U.S. Food and Drug Administration
(FDA) Medical Device Reporting (MDR) regulation (21 CFR
803) contains mandatory requirements for manufacturers,
importers, and device user facilities to report certain device-
related adverse events and product problems. The FDA also
encourages healthcare professionals, patients, caregivers, and
consumers to submit voluntary reports of significant adverse
events or product problems with medical products to Med-
Watch, the FDA’s Safety Information and Adverse Event
Reporting Program.56 Other organizations around the globe
have similar regulations and provide similar reporting systems,
such as Health Canada and the Australian government’s
Therapeutic Goods Administration.
Infiltrative adverse events among patients of all ages and
lens types have been reported to occur at a low incidence
(such as corneal infiltrative event incidence of 21 per 10,000
SCL wearing years).57,58 Specifically, the incidence of events in
children has not been found to be higher than that in adults. In
fact, in the 8- to 11-year age range (a range where myopia
control lenses might become very commonly utilized),
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estimated incidence of events is actually lower than in adults.58
Monitoring, classification, and reporting methods should be
specifically outlined in any research study. Additionally,
practitioners should inform participants and parents of
pediatric wearers about normally anticipated consequences
of contact lens wear, potential adverse events, and what to do
if adverse events occur. Participants (and, in case of child
participants, their parents) should be informed about the
necessity of reporting adverse events.
Pharmaceutical treatment of myopia is associated with
short-term effects such as photophobia and possible long-term
effects such as light-induced retinal damage or cataract
formation.59 The use of atropine for myopia control (0.5%)
resulted in over 80% of children having adverse events
(whether reported by the parents or the children themselves),
such as photophobia (60%–82%), systemic flushes (3%–6%),
infections such as conjunctivitis/blepharitis (0%–3%), head-
aches (7% reported by children who maintained therapy
compared to 31% in those that ceased therapy), and reading
problems (~25% in those who maintained therapy compared
to ~80% in those that ceased therapy).31 Other studies have
reported no serious adverse events.29,32 For pirenzepine
ophthalmic gel (2%), similar mild to moderate adverse events
were experienced in one of two studies, with serious adverse
events deemed unrelated to the treatment.60,61
2.8.2 Ocular Health. At the outset of any clinical trial, a
series of assessments determine baseline data for trial
participants. Baseline information that is collected in a
standardized way can be used for various reasons, including
characterization of participants, analysis of outcomes based on
baseline measurements, and treatment effects based on
presenting characteristics.62 Examples can include presence
or absence of heterophoria, baseline amount of myopia, and
accommodative function. These may inform exclusion criteria
or be used to assess the impact of a myopia control treatment
on ocular physiology. Evaluation of the posterior pole is critical
for all myopia control studies to identify any retinal changes or
pre-existing retinal conditions that may exclude participation
in a clinical trial, require a participant to withdraw from a
clinical trial, or require the participant to be referred for
further assessment. Fundus abnormalities in asymptomatic
patients are uncommon. It has been estimated that fundus
anomalies occur in approximately 2.5% of patients under the
age of 20, with less than 1% of those findings being clinically
significant.63 It is well known that myopia is associated with an
increased risk of many ocular diseases, including myopic
maculopathy, retinal detachment, glaucoma, and cataract.64–67
These risk factors increase with increasing age and increasing
magnitude of myopic refractive error. In a study on myopic
maculopathy, the incidence in patients with a prescription less
myopic than 5.0 D was 0.42%, compared with 25.3% in
patients with more myopic prescriptions.68 Findings have been
similar for the risk of retinal detachments, with an increased
risk in patients with more myopic prescriptions, but even
lower levels of myopia (less myopic than 3.0 D) have been
shown to have a three times increased risk of retinal
detachment compared to emmetropic patients.69 However, all
levels of myopia increase the risk of retinal pathology, so there is
no physiologically safe (or non-pathological) level of myopia
(see accompanying IMI – Defining and Classifying Myopia
Report).70,87
A dilated fundus examination should be performed on
participants at baseline and subsequent annual or periodic
visits. In a study involving pediatric patients, 51% of
participants had one or more peripheral anomalies (albeit
mainly clinically insignificant) that were detected in a dilated
fundus examination that were otherwise undetected in a
nondilated examination.71 The use of a binocular indirect
ophthalmoscope (BIO) is considered the gold-standard for
assessing the peripheral fundus. Typically, a 20 D lens is used in
conjunction with the BIO, but for younger patients, a 28 D lens
can be more useful as it gives a slightly larger field of view.72
A clinical trial involving contact lenses or pharmaceuticals
will require a full anterior assessment at each visit. The slit
lamp biomicroscope offers a variety of illumination techniques
and magnification options to examine the anterior cham-
ber.73,74 A full slit lamp examination utilizes various techniques
in a coordinated, systematic way to ensure a full examination
of all relevant anterior structures; the results should be
recorded with an appropriate grading technique.75
Associations have been reported between myopia progres-
sion, higher levels of esophoria, and accommodative lag in
some studies (see Sections 3.3.2 and 3.3.3), and binocular
vision problems are relatively common in children76,77; thus, it
is important to perform a binocular vision assessment at
baseline (potentially as part of exclusion criteria to ensure they
are not a confounding factor) and at periodic times throughout
a myopia control study, such as during annual assessments.
Typically, participants with a manifest strabismus would be
precluded from participating in a myopia control clinical study,
although this is not always specifically stated in the reported
exclusion criteria (see Section 2.5).
2.8.3 Vision.
2.8.3.1 Visual Acuity. LogMAR visual acuity is measured in
virtually every clinical trial assessing myopia control treat-
ments. It can be both an inclusion/exclusion criterion
(participants need to have a visual acuity better than an
arbitrary value) and to assess any negative (safety) impact of
optical, pharmaceutical, or environmental modifications both
during (reduced vision could affect educational performance
and mobility) and after treatment (permanent visual loss would
be a serious adverse event; see Section 2.8.1). When measuring
visual acuity, considerations include what correction should be
worn (unaided, mean spherical equivalent or full sphero-
cylindrical correction, habitual visual correction or the device),
whether the measures are monocular or binocular and the
target distance (far, near, or a full defocus curve). Contrast
sensitivity is measured in fewer studies, but may be more
sensitive to detect reductions in functional vision.78 Some
studies have shown small reductions in high-contrast visual
acuity and contrast sensitivity when wearing off-label multifo-
cal contact lenses,79 while other studies showed no significant
effects of other multifocal contact lens designs on visual acuity
or contrast sensitivity.80,81 Low dose (0.01%) atropine has
shown no significant effect on visual acuity in young adults
over a 5-day period.82
Some studies use Snellen visual acuity charts and convert to
logMAR, negating the benefits of the standardization and
uniformity of logMAR charts.83 Using Snellen visual acuity is
discouraged for reporting outcomes; studies collecting Snellen
acuity should not convert these to logMAR for reporting,
which gives the false perception that logMAR was collected.
There is considerable variation in the way visual acuity
measurements are expressed (logMAR and decimal notation
can easily be confused), and frequently the charts and the
procedures used for visual acuity testing are inadequately
described.84 As methodology can markedly affect visual acuity
scores, studies should provide enough detail about their
methodologies to allow others to replicate and benchmark
against them.
2.8.3.2 Functional Vision. Reading speed has been found to
correlate better with vision related quality of life (satisfaction
with functional vision) than does traditional high contrast
visual acuity. However, few myopia control studies have used
reading speed, perhaps due to the time taken to conduct the
measurement. Of the studies to assess reading speed to date,
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no difference from controls was found with an off-label
multifocal contact lens design79 or with short-term use of
atropine 0.01% in Caucasian young adults.82 Other aspects of
near work are generally captured in questionnaires85 (see
Section 3.2.1).
2.8.4 Dysphotopsia. Dysphotopsia, such as glare, is of
interest in myopia control strategies that affect light levels,
alter the light spectrum entering the eye, dilate the pupil, or
impose optical junctions (such as different or alternating
power SCL optical zones) within the pupil. However, few
studies have examined the potential adverse effect of
dysphotopsia associated with myopia control strategies. Lough-
man and Flitcroft assessed glare, albeit in a young adult
population over a 5-day use period, 0.01% atropine, showing a
slight increase in symptoms, but no impact on quality of life.82
A recent paper examined the role of short-wavelength filtering
lenses in delaying myopia progression and amelioration of
asthenopia in juveniles, finding no effect over a year’s duration
on refraction or axial length compared to controls, but a
reduction of the effect of glare on contrast sensitivity.86 Future
myopia control studies should elicit whether dysphotopsia has
been increased by the treatment strategy.
2.9 Clinically Meaningful Effect
It is important that similar reporting criteria are utilized across
studies to maximize the comparability of results. The definition
of a clinically meaningful effect is also important for
determining success of any myopia treatment. Another
important question is how large a treatment effect is needed
in each year of a multi-year clinical trial to be considered
meaningful.
The mean and standard deviation of the difference in
progression between groups should be reported for compara-
bility to previously published myopia studies, as well as a
thorough description of the groups and any matching. In
addition to reporting P values, it is important that outcome
papers include the 95% confidence interval for any effect
reported; this allows readers to ascertain the true range of
treatment effect. When stating the percent reduction in
myopia progression or axial elongation between a treatment
and control group, previous studies (see Section 2.1) have
reported treatment effects in the first study year that did not
accrue in subsequent years; therefore, it is critical that the
authors report the time period over which that reduction
occurred (e.g., over 1 year or 3 years). No specific minimum
percent reduction in myopia progression has been published
for a treatment effect to be considered clinically meaningful.
Any percent reduction threshold could vary based on multiple
other factors, including duration of treatment, sample popu-
lation, and study design considerations. However, some
clinicians anecdotally report roughly a 40% reduction in
progression over 3 years as clinically meaningful to them.
That said, evidence shows that any reduction in progression
can be beneficial.70 Of course, it is important to factor the
relative risk of the treatment versus the reduction in risk
provided by reduction in myopia. For example, a treatment
with very low risk of adverse event may have a different
minimum acceptable reduction than one with a higher risk of
adverse event (Fig. 1). A thorough long-term, risk-benefit
analysis is necessary. It is also notable that some children
respond to treatment while others do not. Currently, there
seems to be no way of predicting whether a particular child
will or will not respond. While other ways of evaluating
efficacy—for example, the percentage of children who had a
reduction in myopia progression of 50% compared to the rate
of progression in the control group—may provide additional
information beyond the traditional mean 6 SD and 95%
confidence interval, any arbitrary threshold allows researchers
to find a suitable analysis approach. High myopia (as defined by
the IMI – Defining and Classifying Myopia Report87) could be
taken as a standard way to discuss how many people avoid
developing high myopia as the result of applying a particular
management strategy.
2.10 Sample Size
Sample size based on the axial length effect size with the
different modalities of myopia control treatment are outlined in
Table 4. In many cases, key information was missing from
publications and personal communication with the principal
investigator was required to gain additional statistics.
3. CLINICAL TRIAL OUTCOMES AND RELATED
INSTRUMENTATION
3.1 Primary Outcomes
Clinical trials represent a crucial source of information to guide
the application of basic, clinical, and translational research
toward the health benefit of patients. These trials test a
hypothesis following a chosen treatment. A primary outcome
is arriving at a decision on the overall results of the study,
specifically whether the hypothesis tested is fulfilled.88
Clinically relevant primary outcomes should relate the tested
treatment directly to the patient’s health and be related to
disease scales. Therefore, the primary outcome of a clinical
trial could be a risk/preventative factor for a disease and be
sensitive enough to detect the degree of change expected from
the intervention.89 Coster proposes choosing outcome mea-
sures through creation of a causal model: ‘‘The causal model
makes explicit the researcher’s thinking about how the
intervention is expected to achieve its results—that is, what
the hypothesized mechanism of change is and in which aspects
of the person’s life changes are most likely to be evident.’’89
FIGURE 1. Schematic of considerations that influence the clinically
meaningful effect size.
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Clinical trials in the research field of myopia have utilized
mainly refractive error and axial length as primary outcome
measures, regardless of the intervention: OK,10,17–19,90–92
atropine,30,47,93 or bifocal contact lenses.22,80,94 Additional
secondary outcome measures, such as peripheral refraction,
may be considered depending on the hypothesis being
tested.28 Overall, refractive changes are highly correlated to
eye growth despite the type of myopia control intervention:
under-correction,95 multifocal/bifocal spectacles versus single
vision spectacles,7,13,33,96,97 or bifocal contact lenses versus
single vision.21 However, this is not the case in all studies.98
Early myopia control clinical studies did not measure and
monitor axial elongation,99,100 and those that used ultrasonog-
raphy would have been limited by the resolution of this
technique (~0.30 D),101 making refractive error the preferred
outcome measure in earlier studies. More recently, the
measurement of the biometric components of the eye has
become more widely included and is a key measurement in
myopia control clinics, partly due to the non-invasive nature
and improved resolution (~0.03 D) of the interferometry
measurements for axial length (see Section 3.1.1).101,102
Participantive refraction is more variable than autorefraction,
despite being considered the gold standard for clinical
refraction.103 Changes in refractive error may occur due to
changes in corneal curvature, so when refractive error needs to
be used as the primary outcome measure, corneal curvature
should be measured to help with data interpretation.104
Overnight OK purposely alters corneal topography to target
emmetropia during waking hours, so axial length can be the
only primary outcome measure for the myopia control aspect
of OK myopia control studies.
The advantages of using axial elongation versus refractive
error as the primary outcome measure relates to the direct
relationship between the excessive growth of the myopic eye
and the associated risk for posterior pole complications,
although the two are strongly correlated.105–108 The incidence
of various myopia-related complications (such as temporal
crescents, posterior staphyloma, and chorioretinal atrophy)
increases in parallel with axial length.109 Highly myopic eyes
(axial length ‡27 mm) can show macular Bruch’s membrane
defects associated with complete loss of retinal pigment
epithelium and choriocapillaris, large choroidal vessels, and
marked reduction of photoreceptors, which are strongly
associated with increased axial length.110,111 In addition to
studies in human eyes, experimental myopia induced in fish,
avian, mammal, and primate eyes is also characterized by axial
elongation.112–120 Axial elongation of the eye triggers chorio-
retinal stretching and thinning of the choroid, retina, and
scleral wall,121–126 and increases the risk of developing
posterior staphyloma109 as well as peripheral retinal changes
such as lattice degeneration, pavingstone degeneration, white
with or without pressure, and retinal holes and tears.127 Since
even moderate amounts of myopia significantly increase the
odds of vision-threatening conditions,70 the end goal of all
clinical trials for myopia control should be reduction of axial
elongation (associated with posterior pole complications) to
have the greatest effect on myopic patients’ health status. This
way, a clinically relevant primary outcome is chosen directly
related to patients’ health and disease scales, which could be
used as a risk/preventative factor for the disease.
3.1.1 Axial Length Measurement. Axial length is typically
defined as the axial distance from the anterior cornea to the
retina (exact location within retina varies by technique) along
the line of sight, and this ocular biometric measure is
considered one of the principal biometric correlates of
spherical equivalent refractive error. Numerous studies have
established a strong correlation between the eye’s axial length
and its refractive error.105–108 Myopia development and
progression usually occur due to excessive axial elongation
of the eye, as evidenced by the strong correlation observed
between changes in refractive error (i.e., myopia progression)
and changes in axial length (i.e., axial growth of the
eye).7,96,128 For these reasons, measurements of the change
in axial length in an individual are commonly used as the
primary outcome measure of myopia clinical trials in the
myopia research field.
A range of physiological factors have been documented that
lead to small, but significant, short-term/transient changes in
axial length measures: diurnal variations,129,130 accommoda-
tion131,132 and changes in intraocular pressure.133,134 Clinical
TABLE 4. Sample Size Calculations for Different Modalities of Myopia Control Treatment Based on Axial Length Effect Size
Intervention Author, Year Timescale
AxL Mean
diff (SD)
AxL Min
Sample Size
Per Group
Rx Mean
Diff (SD)
Rx Min
Sample Size
Per Group
Spectacles multifocal Gwiazda et al., 20037 3 years 0.11 mm (SE 0.03) 125 0.20D (SE 0.08) 333
Hasebe et al., 201414 2 years 0.082 mm (0.05) 268 0.27 (0.11) 157
Orthokeratology Kakita et al., 201118 2 years 0.22 mm (0.26) 15–99 NA
Walline et al., 200917 2 years 0.32 mm (1.12) NA
Santodomingo et al., 201220 2 years 0.22 mm (not reported) NA
Cho and Cheung, 201219 2 years 0.27 mm (0.26) NA
Concentric bifocal SCL Lam et al., 201422 2 years 0.11 mm (not reported) 13–69 0.38D (not reported)* 9–?
Aller et al., 201621 1 year 0.19 mm (not reported) 0.57D (not reported)
Pomeda et al., 201723 2 years 0.16 mm (not reported) 0.29D (not reported)
Chamberlain et al., 20176 3 years 0.28 mm (SE 0.04) 0.67D (SE 0.09)
Multifocal SCLs Walline et al., 201728 2 years 0.13 mm (SE 0.04) 16–51 0.52D (SE 0.06) 7–60
Fujikado et al., 201425 1 year 0.05 mm 0.22D
Paune et al., 201526 2 years 0.14 mm 0.42D
Cheng et al., 201627 1 year 0.14 mm 95%CI rep 0.14D 95%CI rep
Atropine 1% Chua et al., 200629 2 years 0.40 mm 95%CI 15 0.92D 95%CI 16
Atropine 0.01% Chia et al., 201230 2 years No control group No control group
Sample size calculation was based on 2 sample t-test comparison with 80% power and P < 0.05 significance level (http://www.statisticalsolu
tions.net/pssTtest_calc.php). SD calculated from SE and n where SE reported. Some cases 95%CI have been reported and not SD or SE. NA, data not
available; AxL, axial length; Rx, refractive error; SD, standard deviation; Diff, difference; Min, minimum.
* 5 or more hours wearing time per day.
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trials assessing axial length should therefore consider the
potential influence of these factors in protocol development,
providing the most reliable measures of axial length and hence
comparisons within and between groups. For example, ideally,
axial length measures collected at approximately the same time
of day would limit the potential confounding influence of
diurnal variations (although these are small)135; however, this
must be balanced by retaining all participants enrolled in a
clinical trial and seeing them for scheduled visits within a
defined visit window. A range of instruments are currently
available for assessment of axial length, and these measure-
ment techniques can be divided into ultrasound and optical
based biometry methods.101,102
3.1.1.1 Ultrasound Biometry. Ultrasonographic methods
for the measurement of intraocular distances were developed
in the 1950s and 1960s,136,137 and some early studies in the
myopia field used ultrasound-based techniques for assessment
of axial length.138,139 Ultrasound biometry involves a transduc-
er directing high frequency (typically 10 mHz in ocular
ultrasound) pulsed sound waves into the eye and recording
echoes of these waves reflected from the ocular structures.
The time delay of these echoes is converted into a geometric
distance through knowledge of the velocity of sound in the
various ocular media. Axial length measurements from
ultrasound instruments are defined as the distance from the
anterior cornea to the inner limiting membrane of the retina.
The properties of ultrasound wave require that the
ultrasound transducer be in contact with the eye, either
directly (in the case of applanation ultrasound) or indirectly
(via immersion of the anterior eye in saline solution for
immersion ultrasound) to take measurements. Studies compar-
ing applanation and immersion ultrasound techniques typically
find lower axial length readings with applanation methods,
which can be attributed to compression of the cornea, leading
to a reduction in the corneal thickness or anterior chamber
depth (ACD) and, hence, axial length.140,141 Ultrasound axial
biometry devices typically provide measurements of axial
length with an accuracy of approximately 0.1 mm.140 Reports
of repeatability with A-scan ultrasonography demonstrate 95%
limits of agreement for test-retest repeatability in the range of
60.2 to 60.3 mm for measures of axial length.142–144
Considering that a 0.1 mm change in axial length is the
equivalent of a refractive change of ~0.3 D, the ability of
ultrasound methods to detect small magnitude changes in axial
length is limited. This relatively coarse repeatability, the need
for corneal anesthesia and contact with the eye, and
dependence on operator expertise to achieve axial alignment
of the transducer145 associated with ultrasound biometry
methods have prompted development of alternative measure-
ment techniques based on optical principles. These newer
methods have largely superseded ultrasound measurements in
the myopia research field.
3.1.1.2 Optical Biometry. The limitations associated with
ultrasound techniques provided the catalyst for development
of optical biometry methods, based upon optical partial
coherence interferometry (PCI) that provide axial length
measures without the need for corneal contact.146,147 In this
method, two partially coherent laser beams are directed into
the eye and reflected back from the ocular tissues. Interference
between the two reflected laser beams forms interference
fringes with peaks corresponding to the eye’s surfaces. The
optical path length between these interference peaks can be
converted into geometric distance based on the presumed
refractive index of the ocular structures. Interferometry
methods define axial length as the distance between the
anterior cornea and the retinal pigment epithelium. It is worth
noting that the use of an assumed average total eye refractive
index will result in some overestimation of axial length when
measures are collected during accommodation (an error of
~0.02 mm was estimated to occur for measures during 10.9 D
of accommodation).148
In addition to the easier alignment and capture of the
measurement due to the technique being non-contact optical
methods have the added advantage of resolution (~0.012 mm)
and precision (~0.01 mm), an order of magnitude better than
ultrasound biometry.101,149,150 Commercially available devices
have test-retest 95% limits of agreement typically reaching
60.04 mm.142,143 Some optical biometers use a super
luminescent diode light source (rather than a laser diode),
improving the signal-to-noise ratio and thus allowing central
corneal thickness, anterior chamber depth, and lens thickness
to be measured at the same level of accuracy rather than
employing image analysis techniques.102,151 Some recent
commercial optical biometers combine highly accurate and
repeatable PCI measurement of axial length with a Scheimp-
flug camera for assessing anterior eye biometry and a Placido
disc corneal topographer.152–155
Optical coherence tomography (OCT) is also utilized to
measure anterior eye biometry, but was originally developed
for cross-sectional imaging of the posterior segment of the eye.
Fourier-domain OCT methods provide high resolution cross-
sectional and volumetric images of the posterior eye with the
ability to precisely resolve individual retinal layers at an
imaging depth of a few millimeters.156 Since the development
of Fourier-domain OCT, a number of methods and prototype
devices have been developed utilizing a range of different
approaches to encompass whole eye OCT imaging and axial
length measurements.157–160 These devices provide rapid high-
resolution measures of axial length, with precision comparable
to other optical methods of axial length measurements.161–163
The advantage of this OCT imaging approach is that these
devices provide cross-sectional images of the eye’s component
structures (cornea, crystalline lens, and retina), providing
additional biometric measures of central corneal thickness,
lens thickness, and anterior chamber depth, thereby allowing
measurement alignment and localization of ocular interfaces to
be more easily verified (with reference to the cross-sectional B-
scan image) than are PCI-based methods.
The non-contact measurements, ease of alignment, and high
precision measures possible with optical biometry methods,
make them ideal for application to clinical trials in the myopia
field. These measurement techniques provide the precision
required to detect small magnitude differences and changes in
axial length in clinical trials. As outlined, there are currently a
number of optical biometry devices commercially available
and, from the point of view of the precision of axial length
measures, most devices exhibit similar performance. One
drawback of optical biometry devices (compared to ultrasound
methods) is that difficulties can be encountered in providing
reliable measures of axial length if dense cataracts are
present,164 but this issue is rarely encountered in the myopia
research field given that the majority of clinical trials enroll
young participants with clear ocular media.
3.1.2 Refractive Error Measurement. In young children,
interpretation of refractive error is complicated by potential
errors in measuring refractive state due to the confounding of
this measurement due to the influence that accommodation
can have on this measurement. The importance of controlling
accommodation becomes apparent when comparing measured
refractive state with and without cycloplegia. Analyzing a
sample of 6017 right eyes of children aged 4 to 15 years, non-
cycloplegic refractions were found to be 0.63 6 0.65 D more
myopic than cycloplegic refractions.165 Twelker and col-
leagues found similar differences in infants (0.89 6 0.66
D).166 These results indicate that noncycloplegic refractions
may overestimate myopia in infants and children; since
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cycloplegic refractions are indeed a necessity of any myopia
control study which has refractive error as a measurement
outcome, most studies determine refractive error as part of
their inclusion criteria using cycloplegic autorefraction (n¼ 17
of studies in Table 1), although this aspect of the methodology
is not always recorded.
As discussed in section 2.6. either 1% cyclopentolate or 1%
tropicamide may be utilized, each with their positives and
negatives. On average, one drop of 1% tropicamide produced
0.14 D more myopic refractive error measures than one drop
of 1% cyclopentolate.46 Yazdani and colleagues167 found a
similar amount in a meta-analysis of six studies, with
tropicamide refractions 0.175 D more myopic. Mutti and
colleagues also found this characteristic (0.20 6 0.30 D) in a
prospective study.168 As between-participant and between-race
differences in the myopic bias of refractions are generally larger
than many of the myopic changes reported in myopia control
studies,21,24,94,169 it is imperative that any study assessing a
myopia control device employ the same cycloplegic proce-
dures for each measure of refractive error throughout.
The reported impact of cycloplegic agents on distance
refractive errors reflect well documented differences between
participants in drug efficacy.170 Specifically, dark irises are
typically associated with reduced drug efficacy.45,171 Also,
because the time course of cycloplegia and mydriasis can
differ,45,171 pupil size should not be used as an indicator of
cycloplegia. It is recommended that clinical trials employing
cycloplegic refractions ensure that refractions are performed at
a fixed time after drug instillation (e.g., 30 or 60 minutes) and
that accommodative status is assessed prior to refractive error
measurements being taken. Tropicamide has been reported to
have a maximal cycloplegic effect at 30 minutes, whereas the
maximal cycloplegic effect of cyclopentolate is reported to be
60 minutes. Given a faster maximal effect and similar reported
cycloplegic effect—despite the possibly increased cycloplegia
of 1% cyclopentolate—most myopia control studies have
utilized 1% tropicamide to obtain their cycloplegic refrac-
tions,21,24 whereas others have used both 1% tropicamide and
1% cyclopentolate.172
Although autorefractors still may have repeatability of
~60.21 D,173 which could encompass a good percentage of
the roughly 0.30 to 0.50 D per-year treatment effect24,94,169
being targeted, autorefractors typically exhibit higher precision
than do participantive refractions (smaller coefficient of
repeatability)174 and minimize unconscious investigator bias.
Because of these aspects, only objective refractions should be
used in myopia control studies. Furthermore, to minimize
variability due to residual accommodation and instrument
myopia, autorefractors should be open-field. To assure they
provide an accurate measure, they should be validated across
their measurement range.175–177 Since myopia control studies
often involve multiple comparisons across several years,
instrument stability is essential across the entire duration of
the study. If possible, this can be accomplished by initial and
continued instrument calibration at specified time frequencies
during data collection according to the instrument manufac-
turers’ recommendations. Specially designed model eyes can
be used for calibration.178,179
As the standard clinical refraction is designed to generate a
single end point, it can be mistakenly assumed that an eye has a
single refractive state. However, due to ocular aberrations,
refractive state can vary significantly across the pupil.180
Therefore, refraction methods that employ a known pupil
location, repeatable across time, are preferred. For example,
eccentric photorefraction and retinoscopy can have their
results affected by aberrations in the pupil margins,181,182
while participantive refractions are biased toward the pupil
center.183 Objective methods that employ a known measure-
ment aperture that can be repeatedly located in (or close to)
the pupil center are recommended.
3.2 Secondary Outcomes
3.2.1 Patient Reported Outcomes. Most myopia control
clinical trials include primary outcome measures that can be
objectively measured (such as an autorefractor measure of
refractive state or biometric measures of axial length; see
section 3.1). However, there are significant insights to be
gained from the child’s wearing experience, effectiveness of
the treatment and understanding the results obtained, by
simultaneously capturing child (participant) or parent-reported
outcomes. Many measures are common to those of typical
contact lens trials, such as assessing comfort, lens awareness,
ease of care, wear time and frequency of problems.184,185 As
myopia control strategies often employ multi-zone optics that
may create ghosting or doubling of images,186–188 other
informative patient-reported outcomes may include visual
quality189 while performing different tasks (such as reading,
computer use, and night vision) and the time to perform these
tasks.184,185 Any participants enrolled in a clinical trial who
discontinue treatment should be queried about the reason for
the discontinuation.
In clinical trials, the reliability of compliance aspects could
be assessed by asking both child and parent/caregiver
separately. The agreement between child and parental/
caregiver responses is not known, especially as it relates to
contact lens use (such as hours of use) and satisfaction.
However, results of behavioral research suggest a low degree of
agreement, and differential levels of agreement believed to be
associated with transitions in age.190 It appears that agreement
between parent and child responses varies with parent
experience. Specifically, in a meta-analysis of 19 studies
(including health-related quality-of-life instruments), parents
with the condition being studied underestimate the child’s
responses, whereas those without the condition reported
higher quality of life than did the child.191 This result may
depend on the specific questions or health-related quality-of-
life instrument. Until more information is available, querying
both child and parent/caregivers is recommended, as each
group will provide valuable information (such as how often a
parent has to assist with insertion of a contact lens).
3.2.2 Assessing Treatment Compliance. It is widely
accepted that compliance with treatment is an important
aspect contributing to the outcome and validity of results in
any clinical trial.192,193 In general, compliance in clinical
studies relates to the adherence with the prescribed regimen
(such as contact lens wear in a myopia control study
investigating the impact of OK). However, there are many
other aspects of compliance, including study visit compliance,
adhering to study procedures, and reporting adverse events.
Literature relating to the impact of compliance on myopia
control clinical trials is sparse. Comparisons can be made with
clinical trials in the medical field, where it is known that non-
compliance may be underestimated.194 Assessment of compli-
ance is affected by how it is measured. For example, a clinical
study involving an anti-depressant drug estimated a compliance
rate of 70% based on evidence of medication in blood samples
drawn from the participants, as compared to 92% using pill
count as the measure of compliance.195 It has been estimated
that up to 30% of clinical trial participants are untruthful about
medication compliance and may be throwing away investiga-
tional product prior to study visits.196,197 This is relevant to
pharmaceutical studies as well as studies involving contact
lenses, in which compliance can be assessed by the number of
lenses used during a specific time period. Participants could be
required to bring all unused product to each appointment so
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the number of remaining lenses can be counted and
compliance based on that count; however, this relies on
compliance with replacement frequency and that no product
is discarded due to damage. It has also been noted that
compliance in clinical studies is generally better in the first few
months of a study and drops off thereafter to a level similar to
compliance in clinical practice. For example, in a study on
children with mild asthma, adherence to the medication
dosage prescribed in the clinical study was 75% at the 3-
month time point but dropped to 53% after 9 months.198
The most common approach to reporting compliance with
prescribed practices (such as taking medication or using a
device on a regular basis) is to collect data retrospectively on
participant activity at the scheduled study visits. This may
result in an inaccurate estimation of information from the
participant or parent, leading to incorrect data, or data that has
to be excluded because the reported information could not be
assumed accurate.199 Participants may not provide accurate
reporting of behavioral information, especially when being
asked to recall from a considerable time period prior to the
study visit.200 Participants who understand the importance of
compliance may choose to modify responses or behaviors to
appear compliant.
In an attempt to minimize errors due to recall, a simple
method of collecting data on activities outside the study visits
is often achieved by means of a questionnaire/diary (such as
nightly or weekly between study visits). There is strong
evidence to support the use of modern technology (electronic
methods) to collect such data. Stone and colleagues reported
that despite participants reporting 90% adherence with that
written in their paper diaries, the actual rate was as low as 11%.
In switching to an electronic diary, the participants are aware
that the information is date and time stamped, increasing
adherence to 94% and reducing the risk of participants
exaggerating their adherence to study protocols.201 Myopia
control studies are typically lengthy, lasting for several years,
with a significant time period between appointments. In
studies involving contact lenses, participants are generally
required to wear lenses for a minimum amount of time and are
often required to self-report their wearing schedule (hours per
day and days per week). This can be undertaken at periodic
intervals between study visits or can be self-reported at each
study visit. Reminders to participants, for example, to
complete diaries about activities or to ensure that they wear
their device for a certain number of hours or days per week,
should promote compliance with study protocols.
In the healthcare field, one simple method of electronic
reporting is possible through text messaging (SMS) partici-
pants. SMS has been found to be both cost effective and
beneficial, with the effectiveness of electronic reminders on
compliance with medical treatment being well documented.
Specifically, Lester and colleagues demonstrated an improve-
ment in HIV treatment outcomes with patients who received
SMS support, and Miloh and colleagues203 demonstrated
significant medication adherence and a reduction in rejection
episodes when text messaging reminders were sent for
pediatric recipients of liver transplants. A systematic literature
review by Vervloet et al.204 confirmed evidence for short-term
effectiveness of SMS electronic reminders, but the long-term
effect remains unclear.202–204 Specifically related to optometric
clinical trials, Morgan reported up to 93% of participants
responding within a 30-minute period of a specified time point
using SMS messaging, and Woods and colleagues demonstrated
a 97.5% response rate to requests for data from participants
generated via smartphone.205,206
Gamification is defined as the process of adding games or
game-like elements to something (such as tasks) to encourage
participation.207 Gamification within the healthcare field is
increasing in popularity and has a positive influence on health
behaviors.208–210 Gamification has been explored as an option
for increasing recruitment, retention, and compliance in
clinical trials. Rowbotham and colleagues211 demonstrated
that interactive media improved comprehension of research
study procedures and risks. Gamification provides a process
of rewarding participants for completing tasks, for example,
diary completion. Virtual rewards take the form of points or
levels and helps drive competitive behavior. In one study
using gamification technology, medication adherence in-
creased from 58% to 95%.212 In a clinical trial setting,
gamification could improve compliance, resulting in more
robust data.
The emergence of wearable technology into the clinical
research space is changing the way in which clinical data can
be obtained. Health and wellness devices are commonly worn
and are a widely accepted accessory. In 2013, there were over
97,000 mobile health apps available to consumers.213 By 2017,
this number increased to 325,000 apps. It has been estimated
that by 2020, there will be 4 million patients using remote
monitoring health technology.214 For the purposes of myopia
control studies, information that can be captured by wearable
technology includes aspects such as time exposed to certain
light levels/spectrums, working distances, and physical activity.
There are several examples in the literature of wearable
technology being used to monitor light levels, and data
obtained from such devices can support assessment of
treatment compliance in studies where treatment relates to
time spent outside.215,216
Participant recruitment and retention are critical to the
success of clinical trials and to the validity of the results.
Participants are generally required to undergo more clinical
procedures than they would in a non-research setting, such as
being required to complete questionnaires and attend more
frequent appointments. It is important from the outset that the
participant—and in many cases the parent/guardian—under-
stands what is required of them for the period of the study. An
understanding of expectations will likely result in better
compliance with the study protocol and better retention of
participants. Where possible, clinical trials should be as
participant-centered as possible, for example, ensuring that
appointment times are convenient for participants. In the case
of studies with children, having appointments available after
school hours or on weekends may be necessary.217,218
Consent forms (or parental permission forms and child
assent forms) that are provided ahead of enrollment should be
simple and written in language that participants can under-
stand since there needs to be an appreciation of expectations
of compliance to study protocol and what would constitute
non-compliance, along with the importance of reporting non-
compliance. It is recommended that informed consent
documents read by adults be written at or below Grade 8
level.219 Adults typically read three to five levels lower than the
school grade level they completed.220,221 When children are
recruited into clinical studies, an ‘‘assent form’’ is used for the
child, and it is imperative that the assent be written in language
appropriate for the age of recruitment. Participants with a
poorer reading grade level than the level of text in the
informed consent form may not understand all of the content
of the document.222 During the recruitment (and follow-up
visits), it is important that the participant trusts the researcher,
understands that reporting non-compliance is a vital part of
study data collection, and that this does not reflect poorly on
the participant. Study participants may not want to let the
researcher know that they have been non-compliant, as this
may ‘‘disappoint’’ the researcher or result in them being
withdrawn from the study.
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3.3 Exploratory Outcomes
While axial length and refractive error are well established as
primary outcome measures of myopia control trials, an
increasing number of exploratory outcomes have been
adopted to aid in the prediction of efficacy for individuals, to
better understand the mechanism of control, or to investigate
safety aspects. These exploratory outcomes may sometimes be
specific to testing different hypotheses associated with
different myopia control approaches: peripheral refraction,
accommodative changes, ocular alignment, and posterior
segment imaging to optical myopia control techniques;
accommodative changes and pupil size to current pharmaceu-
tical approaches; outdoor activities to myopia control environ-
mental policies; and anterior segment imaging and tissue
biomechanics to OK.
3.3.1 Peripheral Refraction. In 1801, Thomas Young223
estimated the astigmatic image shells in a model of his own
eye. Hoogerheide and colleagues224 suggested that certain
patterns of peripheral refraction—involving the peripheral
retina being less myopic or more hyperopic than the central
retina—could predispose an eye to development of myopia.
Several studies on different animal models have since shown
that image quality on the peripheral retina can regulate ocular
growth in chickens,113,115 monkeys,225–229 and guinea pigs120
and that an eye with peripheral hyperopia continues to grow
even though the central image is well-focused on the fovea.229
The review by Wallman and Winawer230 has inspired many
investigations of human peripheral refraction, and the interest
in refraction has extended to include higher-order aberrations.
Relative peripheral refraction is a surrogate for eye shape, but
it does not describe the optical experience thought to regulate
eye growth.
As described earlier for central (foveal) refraction, the
peripheral refraction is preferably measured with accommo-
dations paralyzed to avoid changes in the optical profile (see
review by Lundström and Rosén231). Furthermore, it is
practical to express peripheral refractions in terms of mean
sphere and two astigmatic components232:
M ¼ Sþ C=2
J180 ¼  C=2ð Þcos 2að Þ
J45 ¼  C=2ð Þsin 2að Þ
with S/C 3 a being the sphere/cylinder/axis format. In the M,
J180, J45 format, statistical analysis is easy to perform and at any
appropriate time conversion can be reverted back to S/C 3 a
format. As well as absolute values, relative peripheral refraction
is often specified in which central M is subtracted from
peripheral refraction M values.
Studies of the peripheral refraction in human eyes have
shown a consistent difference at the group level between eyes
of different central refractive states; myopic eyes tend to have a
more hyperopic relative peripheral refraction (typically around
þ1.00 D in the 308 temporal visual field) than do emmetropic
and hyperopic eyes (typically between 0 and1.00 D), but the
variation between individuals can be large.231 These differenc-
es may be largely a consequence of the excessive eye growth,
causing myopic eyes to be more elongated relative to
emmetropic eyes,106 and the hypothesis that peripheral
refraction of the uncorrected eye may be used to predict
which children might develop myopia224 has not been
supported in clinical studies.233–236
It is difficult to give criteria for differences or changes in
peripheral refraction pattern that could be considered
clinically significant. To the best of our knowledge, no such
criteria have been suggested. Several studies have made
group or treatment comparisons at individual field locations,
mostly along the horizontal visual field and at angles from
6108 to 6408. Note that relative effects will be more
pronounced as one moves further from fixation. Values have
high interparticipant variation in the region of 158 into the
temporal field, corresponding to the optic disk on the retina;
these are usually discounted in analysis. A related issue is
how far from fixation that peripheral refraction would be
considered relevant to development and progression of
myopia; in this regard, Mathur and Atchison237 suggested
an outer horizontal meridian limit of 408 from fixation as
beyond that angle many adult emmetropes had a pattern of
relative peripheral hyperopia. A relevant angle could be 308
in the temporal visual field, in which myopic and emme-
tropic eyes tend to be separated by less than 2.00 D, as
mentioned above. Therefore, 2.00 D would set the upper
limit for a criterion on differences in relative peripheral
refraction of practical significance. The lower limit for a
criterion could be set by depth-of-field, which increases with
eccentricity as both astigmatism and higher-order aberrations
increase in magnitude off-axis231; at 308 temporal visual field
astigmatism gives a Sturm’s interval of around 1.00 to 2.00 D.
In this context, it should also be noted that the most common
design of optical corrections for myopia prevention cause
further increases in the depth of field.238 With this reasoning,
a criterion on differences in relative peripheral refraction of
practical significance at 308 temporal visual field could be in
the order of 0.50 to 1.00 D. However, it may be more relevant
to the emmetropization process to compare different
peripheral field meridians with each other instead of with
the fovea, such as asymmetries between the temporal and the
nasal visual fields.239,240
In addition to uncorrected peripheral refraction, there is
also interest in measuring corrected peripheral refraction
(peripheral defocus) after OK and while wearing a contact
lens. Myopic peripheral defocus has been hypothesized to
slow myopia progression. Although relative peripheral
refraction of the uncorrected eye may not be associated with
myopia onset or progression (see previous), some longitudi-
nal studies have reported an association between peripheral
refraction while wearing correction and myopia progres-
sion.94,241 Standard spectacles can increase peripheral hyper-
opic defocus,37,39,242 while multifocal spectacles and contact
lenses can cause myopic peripheral defocus.241,243,244 The
use of autorefraction to determine the effect of a particular
optical device on peripheral defocus may be of interest as a
secondary outcome in studies trying to determine factors that
may predict which eyes respond best to a myopia control lens
design. Standardized measurement methods are needed in
such studies.
Peripheral refraction has been determined by several
methods, including variations of participantive refraction,
retinoscopy, manual optometers (such as the Zeiss coincidence
and parallax optometers), the double-pass point-spread func-
tion, photorefractors, autorefractors, and aberrometers.231,245
Participantive refraction is challenging because of reduced
retinal function making judgments difficult, so there are few
reports.237,246–248 Retinoscopy, which has been used since the
late 19th century,249 requires considerable examiner skill and
is not as repeatable as autorefraction.250
In applications of these techniques, the eye is often rotated
to align the measurement axis of the instrument with the
desired visual field location. It is common to set up external
fixation targets along the horizontal visual field for open-field
autorefractors. However, a large eye rotation will alter
muscular stress as well as eyelid pressure on the eyeball,
potentially causing optical changes,251–253 although such
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changes have not been noted in more recent studies.254–256 In
the case of contact lenses, it should also be noted that El-Nimri
and Walline257 found that eye movements can cause shifts in
soft contact lenses by more than 0.5 mm, and thus have the
potential to affect peripheral refraction measurements. It is
recommended that (where possible and without slowing
measurement time) eye movements should be limited during
peripheral refraction testing, especially when measuring at
large angles.
The main instruments used to determine refraction in the
peripheral visual field in the last 15 years are commercial open-
field autorefractors, mainly Shin-Nippon (Osaka, Japan), Grand
Seiko instruments (Mahwah, NJ, USA), and Hartmann-Shack
wavefront sensors (such as Thorlab, Inc., Newton, NJ, USA),
while the latter can also be used to determine higher-order
aberrations. A few laboratories have developed ‘‘automated’’
instruments to shorten measurement time.258–260 There are
issues associated with each type of instrument for peripheral
measurement, for which they were not designed:
3.3.1.1 Autorefractors. The Shin-Nippon and Grand-Seiko
instruments record refraction corresponding to an annulus in
the pupil of 2.3 to 3.0 mm177; imprecise positioning over
refractive corrections with narrow optical zones could lead to
erroneous measurements, although consistency has been
demonstrated with accurate placement.261 When there are
rapid changes in the optics across the field, the measured
refraction does not keep pace. The extreme case is when there
is a discrete change in the optics, such as occurs with
concentric bifocal intraocular lenses and contact lenses (a
central zone is responsible for distance vision and a peripheral
zone is responsible for near vision, or vice versa). Other
examples are when corneal shape is altered by refractive
surgery262,263 or OK.264,265,266 As long as it is understood that
there is a lag in refraction changes into the periphery, this is
not a major concern. When planning clinical trials, it is also
important to recognize that repeatability of autorefraction
declines when further measurements are made in the
periphery in both normal eyes173 and in eyes that have
undergone OK.172
The majority of peripheral refraction measurements with
the instruments have been along the horizontal meridian,
with few measurements along the vertical meridian239,267
and only one study has considered oblique meridians.268
Osuagwu and colleagues269 found that higher-order aberra-
tions, such as coma, affect the shape of the retina image for
oblique meridians, consequently affecting refraction mea-
surement along these meridians. While this was investigated
with the Shin-Nippon/Grand Seiko SRW-5000 with an
analyzing pupil annulus of 3.0 mm diameter, and may be of
less consequence with newer versions such the Shin-Nippon
NVision K-5001/Grand Seiko WR-5100K with a smaller 2.3
mm analyzing pupil, the authors recommended that autore-
fractors should not be used to determine peripheral
refraction along oblique meridians and advised that instru-
ments be validated before being used outside the scope
intended by the manufacturer.
3.3.1.2 Wavefront Sensors. The size and shape of the pupil
used in analysis is important. The pupil is mostly circular on-
axis, but when viewed off-axis, it becomes elliptical in shape,
making traditional methods of power determination utilizing a
Zernike fitting problematic.237 Alternatives in dealing with this
approach and using a Zernike fit include using an elliptical
pupil shape stretched along its minor axis to become a circle,
or using a circular pupil whose diameter matches either the
larger or smaller dimensions of the elliptical pupil. These
different approaches will give different errors and estimations
of aberrations. Aberrations, although with correct manipula-
tion, they will give similar estimates of refraction from even-
order Zernike aberration coefficients. Comparison and conver-
sion code for the different estimations were given by
Lundström, Gustafsson, and Unsbo.240 Based on simplicity of
approach, possible departures of off-axis pupils from ellipticity
and ease of understanding, a circular pupil approach based on
a diameter that fits within the actual pupil should be
adopted.231,270 Alternatively, as this approach may bias the
results to the central optics—of possible importance when
measuring through center-surround zonal lenses—Zernike
fitting could be avoided all together by either determining
refractive power based on the local slope/zonal integration271
or by calculating the wavefront vergence based on the raw
slope measured by the instrument.272
Charman and colleagues270 argued that visual field (such as
superior visual field) rather than a retinal (such as inferior
retina) reference be used when describing peripheral refrac-
tion measures. Specifically, the angles associated with each
measure and distances from fixation should be specified in
terms of object space rather than within the eye. For sign
convention, most peripheral refraction studies have assigned
positive values to the nasal visual field and the superior visual
field.231 It has been suggested that the ophthalmic optics
convention of determining visual field meridian in terms of an
anticlockwise angle (from the right side when viewing a
patient’s eye) be adopted, in which case the eccentricity does
not require a sign.270
Peripheral aberration coefficients across the visual field
show considerable mirror symmetry between right and left
eyes.269,273 In a pooled data set (such as when combining
temporal visual data of right and left eyes and combining nasal
visual data of right and left eyes), the coefficients with negative
correlations between right and left eyes require sign changes
for left eyes. The correction needed is that used for positions in
the pupil for on-axis aberrations as specified in the ISO
standard for ophthalmic wave aberrations.274 Specifically, signs
of left eye coefficients are altered for which the Zernike
polynomial functions Zmn (m¼ radial degree and n¼ azimuthal
degree) have negative, even m-indices or positive, odd m-
indices, such as for C22 , C
1
3 , C
3
3 , C
4
4 , and C
2
4 (the coefficients
for oblique astigmatism, coma, trefoil, and oblique secondary
astigmatism, respectively).
Another consideration is the same issue described above
relating to autorefractors regarding the effect of rapid spatial
changes in the optics during refraction measurements. In the
case of ‘‘regular’’ changes such as OK, the analysis pupil size
can be varied to more clearly show changes in refraction; for
example, analyzing with a 2-mm pupil rather than a 3-mm
pupil will show more rapid changes and better reflect changes
in corneal surface shape. However, there will be problems with
discrete changes. Figures 2 and 3 show spot diagrams and wave
aberration maps for a theoretical example of a distance-center
bifocal lens combined with a model eye, in which the center
and peripheral contact lens zones contribute in varying
amounts to imaging and the determination of aberrations as
the horizontal visual field angle changes. How a particular
instrument deals with this depends on its sampling density, its
algorithms for determining transverse aberrations, and Zernike
wave aberration fitting. Clearly, there is no oblique astigmatism
here, but one paper has reported considerable, artifactual,
oblique astigmatism (J45) for a distance-center lens rising to
»0.70 D at about 258 horizontally from the center of the
field.275 The problem is the inadequacy of fitting Zernike
aberration polynomials with these lenses with multiple or
discrete zones. A partial solution for measuring refractions
through such lenses is to determine refractions from Zernike
circular polynomials obtained using small pupils (such as 1
mm) and ignore discontinuities corresponding to zone
boundaries. Alternatively, more elaborated image quality
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metrics than those calculated directly from the Zernike
coefficients could be used when analyzing the peripheral
optical effect of these lenses. Rosén and colleagues238 used the
area under the MTF curve for a 4-mm pupil diameter, which
provides a more complete description of retinal image quality,
reflecting the ambiguity of defining the far point with a
discrete change in refraction over the pupil. Additionally, as
described, refractive power could be obtained based on
calculations from the local slope/zonal integration271 or by
calculating the wavefront vergence based on the raw slope
measured by the instrument.272
3.3.2 Accommodation Changes With Optical Devices.
3.3.2.1 Lag of Accommodation. Accommodation lag is
usually measured participantively with MEM or Nott retinos-
copy, or objectively277 with an open-field autorefrac-
tor81,278–281 or wavefront aberrometer,282 with the
participant viewing through their distance correction (or
spherical equivalent lenses). The lag of accommodation is
calculated as the change in measured refraction from distance
viewing subtracted from the anticipated accommodative
demand related to the target distance.28,282 If the measurement
of accommodative response is derived from aberrations over a
particular pupil size, then, for the measurements to be
accurate, the change in the individual’s eye focus should be
weighted to their dynamic pupil changes.283 To fully drive the
accommodative system, the target should be high contrast and
close to the maximal visual acuity threshold.284 Alternatives
include using fused cross-cylinders,86 monocular estimate
method,285 and Nott retinoscopy, all of which are less accurate
and repeatable.277
3.3.2.2 Dynamic Changes of Accommodation. Accommo-
dation is a dynamic process and allows pre-presbyopes to focus
across a range of distances. Dynamic changes of accommoda-
tion can be measured with open-field autorefractors (including
photoretinscopy)286–288 and aberrometers,289 but this has not
been adopted in current myopia control studies. However,
dynamics of accommodation will affect the peripheral retinal
image focus, which could impact on the treatment effect if
based on the peripheral refraction hypothesis.
3.3.3 Ocular Alignment. While most bifocal or progres-
sive multifocal spectacle studies have reported only minimal
reductions in myopia progression, larger reductions in
progression have been reported in children with nearpoint
esophoria or accommodative dysfunctions.96,290 Multifocal
contact lenses worn by children can induce exophoria,
increasing with accommodative demand.79 OK causes minimal
effects on ocular alignment,291 and a link between OK or
pharmacological treatments for myopia control has not been
reported. These results indicate some potential benefit of
monitoring heterophoria either upon inclusion in a study or
during the course of the study.
Heterophoria has been assessed in myopia control treat-
ment evaluations in a variety of ways, including alternating
cover test,21 ,280 ,292,293 Howell-Dwyer near phoria
card,33,294,295 Maddox wing/rod,293,296 prism dissociation,81
and von Graefe and modified Thorington techniques.79,83,297
FIGURE 2. Spot diagrams for a distance-center bifocal contact lens combined with the Navarro schematic eye,276 as a function of horizontal visual
field angle. Out of the eye raytracing, distance power 0D, additionþ2D, center zone diameter 2 mm, refractive index 1.43, pupil size 3 mm, back
surface of contact lens is that of the cornea at 7.72 mm. Drawn with Zemax OpticStudio 16.5 SP1 (Zemax, LLC, Kirkland, WA, USA).
FIGURE 3. Wave aberration maps in the exit pupil plane for a distance-center bifocal contact lens combined with the Navarro schematic eye.
Conditions are the same as for Figure 2. Drawn with Zemax OpticStudio 16.5 SP1 (Zemax, LLC).
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Different free-space heterophoria measuring techniques do not
give equivalent values.298 The modified Thorington technique
(a tangent scale technique for assessing dissociated phoria) has
been shown to be the most repeatable of the established
techniques for phoria assessment, with good inter- and intra-
examiner reliability.298,299
3.3.4 Pupil Size. Pupillometry is a critical measure in most
myopia clinical trials due to the limitation of the pupils on the
transfer of the effects of optical interventions onto the
retina,300 or to assess the adverse muscarinic receptor effect
of myopia control drugs.82 Pupil size is also critical in modeling
ocular aberrations (see ‘‘Clinical Trial Outcomes and Related
Instrumentation: Primary Outcomes’’). Pupil size can be
estimated participantively and its dynamics checked with a
light source82 but is better measured objectively using
dedicated pupillometers,30,47,301,302 some biometers303 or
aberrometers/topographers.304 Pupil size varies with task and
light levels, so it is complicated to analyze and report.
However, measurements are not often reported.
3.3.5 Outdoor Activity/Light Levels. The rapid increase
in myopia prevalence seen over the last few decades305
implicates a change in the environment as the primary causal
agent for the current global myopia epidemic. However, the
obvious geographic and racial differences in reported myopia
prevalence and severity (such as very high prevalence, early
onset, and high levels in East Asia), and the familial clustering
of myopia306–309 are consistent with genetics playing a
significant role. Increased levels of myopia in racial subgroups
within racially mixed societies, such as Australia and Singa-
pore,310–312 are also consistent with genetics playing a role.
The hybrid hypothesis proposes that environmental changes
over the last few decades in combination with a genetic
susceptibility (those with East Asian genes or with the genetics
from myopic parents) have jointly contributed to the current
myopia epidemic.305,313 Sorting out these competing hypoth-
eses is a classic nature-versus-nurture challenge for the
research community.
If environmental changes are responsible for elevated levels
of myopia, what characteristics of the environment are
responsible? Experimental studies on animals support the
hypothesis that the retina plays the central role in regulating
eye growth (see accompanying IMI – Report on Experimental
Models of Emmetropization and Myopia).314 Also, there is
evidence that retina-specific environmental factors contribute
to myopia development in humans, such as retinal light
exposure of microscopists315 and retinal deprivation from
ptosis/cataract.316 It is likely, therefore, that changes in the
light environment (intensity, spectral content, optical distance)
have contributed to this epidemic, rather than non-visual
environmental factors such as air pollution and diet (see
accompanying IMI – Interventions for Controlling Myopia
Onset and Progression Report).317
Establishing a causal relationship between environmental
factors and myopia development is challenging for several
reasons:
1. The significant covariance of many factors potentially
involved in myopia development, such as more time
outside, will always be negatively correlated with less
time inside.
2. Activities are generally different in indoor and outdoor
environments. Sporting or other physical activities
involving distant visual stimuli are common in the
outdoor environment, whereas physically sedentary
activities (such as watching TV and reading) combined
with near viewing are common in interior environments.
It is important to recognize that small differences in near
viewing distances can dramatically alter the optical
stimulus (target vergence), the accommodative response,
and the defocus experienced by the eye.
3. Myopia development is slow (typically <1.0 D per
year128,318), and refractive measures have coefficients of
repeatability of about this magnitude, necessitating
multi-year monitoring. On the other hand, measures of
axial length have higher precision149 and can reliably
detect smaller changes in myopia progression (such as
those occurring over shorter periods of time).
4. Most studies assessing outdoor exposure time have
employed survey tools. These questionnaires have
ranged from a single question on outdoor activity319 to
more detailed questionnaires estimating time engaged in
a range of leisure and sporting outdoor activities on
weekdays and weekends as utilized in the Sydney Myopia
study320; however, accurate measures of the multidimen-
sional properties of the visual environmental experi-
enced by children are difficult to infer from these survey
tools321 since they cannot quantify key parameters such
as light level or viewing distance and are participant to
recall bias.322 Studies have noted that there is generally
poor agreement between outdoor exposure time derived
from questionnaires and outdoor time derived from
objective measures of outdoor light exposure.216,323
5. Standard corrections for myopia (such as single vision
spectacle or contact lens corrections) may also alter
retinal experience. This has also raised the question of
whether traditional myopia treatments somehow con-
tribute to the myopia progression of control groups in a
clinical trial.324
6. Modern techniques have been able to quantify personal
environmental light levels using wearable photodetec-
tors216,325 and physical activity levels using accelerom-
eters,325,326 providing the ability to give objective
measures of outdoor exposure times in children.
However, characteristics of the light environment
determining the retinal image characteristics have not
been specifically quantified. For example, because of the
brow, the eye generally does not experience direct solar
irradiation, whereas a light detector mounted on clothes
can be directly illuminated by the sun. Will body-
mounted light monitoring systems accurately reflect
the true retinal illumination?
Some recent studies examining the relationship between
myopia and outdoor activities have employed a range of
different objective devices to estimate outdoor exposure,
including wearable light sensors affixed to clothing (such as
HOBO Pendant light loggers; Microdaq.com Ltd, USA)216,323,327
and wristwatch sensors that combine light sensors and
measures of physical activity (such as Actiwatch devices;
Philips Respironics, Andover, MA, USA)325,328,329 and the
recently developed FitSight fitness tracker (Singapore Eye
Research Institute, Singapore).215 These wearable sensors
provide detailed objective assessments of light exposure
patterns. Through continuous measures of light exposure,
and current device battery life and data storage capacity, the
devices can be worn for up to a month (recharging devices and
the ability to wirelessly synchronize data to other smart devices
should allow longer measurement periods). The majority of
studies employing wearable light sensors to provide objective
measures of outdoor exposure time have utilized a light
intensity cutoff value of >1000 lux to delineate between
outdoor and indoor exposure, since light levels >1000 lux are
not commonly experienced when indoors.215,216,323,325,328 A
recent study comparing light exposure measures (collected
with a wristwatch light sensor) derived from a range of
sampling frequencies and durations has recommended that for
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the most reliable measures of outdoor light exposure in
children and adults, light exposure measures should be
collected for at least a week with measurements sampled at
least every 2 minutes.330 Recent technological advances also
enable accurate monitoring of real-time viewing distances, to
allow the dioptric mapping of the visual environment, which
helps reveal any potential relationship between chronic
viewing distances and myopia development.329,331–333
Finally, although the preponderance of evidence supports
the idea that increased outdoor activities and, by necessity,
decreased indoor time, are associated with lower levels of
myopia,320,322 most of these studies can reveal only an
association. A number of recent interventional studies have
also shown that interventions to increase children’s daily
outdoor exposure time have resulted in significant reductions
in myopia development compared to control groups.334–336 Of
course, there are some potentially confounding causal rela-
tionships (such as hyperopic children are less likely to read
because of the increased accommodative demands and
possible fusional failures that can result).337 Are these children
more likely to spend time outside because of their refractive
state and not vice versa? Further, because many outdoor
activities require distance vision (such as playing cricket and
baseball), children with myopia may be less inclined to
participate in outdoor activities, again suggesting that it could
be the refractive state causing the environmental differences
and not the other way around.
If myopia levels and progression are dominated by the
refractive state at the start of a study, then environmental
experiences prior to the emergence of myopia may be the
causal agent,338 which is consistent with the key conclusion of
Xiong and colleagues,322 that outdoor activity can protect
against the onset of myopia but not its progression. These
results suggest that environmental studies of children prior to
the ages typically associated with myopia onset might be
required to reveal environmental factors responsible for
myopia onset. Another issue may be reliance on inaccurate
measures of time spent outdoors,321 inadequate number of
data samples,339 and body-mounted light dosimeters that might
misrepresent the amount of light in the retinal image.340
Because outdoor activities are often very different from
those practiced indoors, activity becomes a significant
covariable for environmental light levels. For example, in
studies that did not directly measure physical activity,341 the
significant association between emerging myopia and outdoor
sports cannot be separated from the light exposure covariable.
Studies that surveyed activities as well as time outside320 made
tentative conclusions that it was more outdoor time and not
sporting activities that were responsible for lower myopia rates
in children. More recent studies that actually measured
physical activity328,342 failed to find any association between
physical activity and myopia development.
Given the impact of light exposure and outdoor activities
upon eye growth, there is potential for differences in outdoor
exposure to interact with treatment effects in clinical myopia
control trials. Clearly, the collection of detailed data to estimate
outdoor time or light exposure in treatment and control
populations is imperative for clinical myopia control trials
involving interventions. In addition, during myopia clinical
trials of optical devices or pharmacological agents, the season
in which the study is commenced and measurements are
collected should be at consistent times of the year for each
child in a multi-year study. Nonetheless, measures at other time
points throughout the year may be beneficial in supplementing
annual measures since it is likely that enrollment in longitu-
dinal clinical trials will stretch across multiple seasons.
3.3.6 Anterior Segment Imaging. Scheimpflug imaging
and Optical Coherence Tomography (OCT) have been
extensively utilized to examine differences in the anterior
chamber with refractive error, although they are not generally
used to assess myopia control techniques. Longer axial length
is associated with a flatter corneal curvature, decreased
corneal thickness and decreased endothelial density.343–346
Some studies have found that eyes with high myopia have
thinner corneas than eyes with emmetropia or other refractive
errors,347 whereas other studies showed no relationship
between refractive error and corneal thickness.348 Anterior
chamber depth has been found to be deeper in myopic
eyes,346,347,349,350 creating an increase in anterior chamber
volume.351–353
Several studies have reported the ciliary muscle, as imaged
by OCT, to be thicker in myopic than in emmetropic
eyes,354–358 whereas others have not found a significant effect
of a longer axial length on ciliary muscle thickness.359 Ciliary
muscle thickness has been shown to be thicker temporally
than nasally with an association with refractive error in
humans.359 Ciliary muscle ring diameter increases (by 0.10
mm/D), the anterior lens surface steepens (by 0.011 mm/
D),360 and crystalline lens depth from the anterior chamber
decreases352 with increasing myopia. Changes in the anterior
chamber depth with accommodation are significantly less
pronounced in eyes with high myopia than in emmetropic
eyes, but in some myopic eyes accommodation caused the
anterior chamber to become critically shallow.361
Studies utilizing Scheimpflug imaging have shown that OK
lens wear alters the anterior corneal shape rather than the
posterior corneal shape and the anterior chamber depth,362,363
although one study noted a slight flattening of the posterior
corneal surface over 1 year.364 However, Chen et al.365
observed that steepening of the posterior cornea was observed
immediately after lens removal, and it returned to its original
shape within 2 hours after cessation of lens wear. Anterior
segment biometric depths do not appear to change over either
short-term (6 months)366 or long-term (2 years)367 OK,
although axial length increases significantly. High resolution
Scheimpflug imaging can calculate corneal power from its
shape profile and, using this technique, has demonstrated that
axial elongation over time is slower with greater OK-induced
changes in refractive power between the central to the mid-
peripheral cornea.368
3.3.7 Posterior Segment Imaging. Since changes in
posterior eye structures (such as the retina, choroid, and the
optic nerve head) are known to accompany myo-
pia,121,124,126,369–371 imaging of posterior segment structures
and the assessment of quantitative changes in posterior eye
tissues are useful adjuncts to measures of refraction and axial
length in myopia clinical trials. These measures provide
insights into the mechanisms underlying observed refractive
and eye length changes, and they contribute toward under-
standing the association between myopia and the development
of posterior segment ocular pathology.372 While there is a
variety of instruments available for the assessment of the
posterior segment (such as ultrasound), the ability of Fourier-
domain OCT to provide non-invasive, high-resolution posterior
segment images allowing quantitative measures of both the
retina (and individual retinal layers), choroid, and optic nerve,
makes this an ideal technology for assessing posterior segment
ocular structures in myopia research.
Standard OCT imaging methods were designed to optimize
retinal imaging; therefore, studies to quantify choroidal
parameters should employ additional methods to optimize
the image of the choroid and visibility of the chorio-scleral
interface.373 Imaging techniques such as B-scan frame averag-
ing and enhanced depth imaging are available on a number of
commercial OCT devices for improving imaging of the choroid,
and OCT’s with longer wavelength light sources (for example,
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1050 nm) also provide enhanced visibility of the choroid.374 A
number of factors can influence the reliability of quantitative
retinal, choroidal, and optic nerve measures from OCT images,
such as the density of B-scans used to sample a retinal region,
the registration of scan locations (within and between
participants), magnification factors associated with differences
in refractive error and axial length, refractive index assump-
tions, and between-participant variations in anatomical factors
such as the disc-fovea angle.375,376 These potential confound-
ing factors should be considered in clinical trials employing
OCT imaging to draw the most reliable inferences from data.
OCT image segmentation also often requires some manual
checking by expert graders (particularly for choroidal mea-
surements). Appropriate masking of image graders is required.
Clinical trials assessing pharmacological or surgical-based
myopia control interventions should also include posterior
segment imaging to assess the potential for such treatments
resulting in any adverse effects to the posterior segment (for
example, retinal toxicity). While fundus photography and
ophthalmoscopy are typically employed in clinical trials to
assess adverse retinal effects associated with pharmacological
treatments, additional retinal measures—such as fundus
autofluorescence, OCT imaging, and electroretinogram tech-
niques—provide additional structural and functional retinal
measures that are useful in the assessment of possible retinal
toxicity.377,378
3.3.7.1 Retinal Contour Determination. Methods for
assessing ocular biometry and imaging the posterior segment
can also be used to derive measures of retinal shape.379 Retinal
shape is an important factor influencing peripheral refrac-
tion.373 Retinal shape has been considered for emmetropic
versus myopic eyes, in different races, and for retinal
asymmetry. In the future, it could be used to monitor the
effects of treatments as something more sophisticated than
determining changes in axial length. Retinal shape has been
determined by several methods, including X-ray radiography,
ultrasonography, computerized X-ray tomography, partial
coherence tomography, OCT, and magnetic resonance imaging
(MRI).380
A direct way of determining retinal shape is with the use of
MRI, which is not affected by imaging through the eye but has
low resolution on the order of 0.25 mm in-plane.381 A number
of factors determine resolution, including the types and
configuration of the radio-frequency coils used to transmit
and receive the radio-frequency pulses, the imaging pulse
sequences employed, and whether 2-dimensional or 3-dimen-
sional data are required. Fine features such as the foveal pit
cannot be resolved, meaning that estimations have to be made
of the visual axis. It is somewhat impractical for clinical trials
due to its testing time, current poor availability, and high
expense.
Because of optical distortions, methods such as partial
coherence tomography and OCT must be combined with other
biometric measurements and with ray tracing based on optical
eye models. These methods seem promising in approximating
measures of retinal shape obtained from MRI.379,382 While MRI
can yield good eye shape estimates for the majority of retinas, it
is probably not that helpful for restricted regions of the retina
corresponding to the 6308 field in which peripheral refraction
measurements are usually made383; the other methods may be
of more value for such restricted regions.
Different estimates of retinal shape have been made. These
include ratios of axial length to the horizontal and vertical
dimensions (the latter two usually measured from one side of
the retina to the other),106 ellipse or ellipsoidal dimensions
giving estimates of surface asphericity,383,384 type of retinal
stretching in myopia (such as global, equatorial, posterior
polar, and axial),380 retinal asymmetry such as comparing
retinal distances to a nodal point in different meridians,381 and
inferences of the overall eye shape as being oblate or prolate
on the basis of an eye having relative peripheral myopia or
relative peripheral hyperopia, respectively.
3.3.8 Tissue Biomechanics.
3.3.8.1 Sclera. Scleral biomechanical changes are known to
occur with increasing levels of myopia in the human
eye.385–387 Specifically, axial elongation has been found to be
associated with weakened biomechanical properties of the
posterior sclera.388 It is unclear whether these biomechanical
changes are a precursor to or a consequence of myopia. It is
proposed that an accurate non-invasive assessment of material
properties of the sclera in vivo would enable early detection
and monitoring of eyes at risk of developing myopia as well as
improving our understanding of the mechanism by which
these alterations occur.
Non-invasive strategies with potential clinical applications
have included: MRI imaging,389 anterior OCT,390 indentation
tonometry,391 ocular and fundus pulse amplitudes,392 ultra-
sound elastography,393 assessment of axial length changes
following manipulation of external pressure,394 and internal
IOP.395 Despite such attempts, most of these methodologies
are crude and lack the accuracy and sensitivity needed to
identify changes in tissues strength between myopic and non-
myopic eyes.396
With the growing popularity of corneal collagen cross-
linking (CXL) for treating keratoconus, there is interest in the
application of CXL to the sclera to possibly arrest axial
growth.397 Thus far, scleral CXL has been assessed only in
animal models, with early results showing increased biome-
chanical strength and reduced rate of myopic changes.398,399
At present, if CXL is applied to the in vivo human sclera due to
technical limitations in assessing scleral biomechanics, out-
come measures are likely to be limited to biometry and
refractive error changes.
3.3.8.2 Cornea. Given that the biomechanical assessment of
the in vivo sclera is limited, much of the research relating to
myopia and ocular biomechanics concerns the cornea. As both
structures are predominantly composed of collagen and have
similar embryological origins, it is generally assumed that
scleral biomechanical changes may translate into corneal
alterations.400 The validity of this assumption is unclear and
there is significant ambiguity in the literature as to whether
corneal structural and biomechanical changes occur in
myopia.401–403 Nonetheless, it is widely agreed that corneal
biomechanics is important in OK and considered to be a
significant outcome measure.404,405 Indeed, improved under-
standing of how biomechanics of the anterior ocular surface
vary during myopic OK will provide a better understanding of
the role of tissue biomechanics in the corneal shape change
induced during treatment. Biomechanics can also inform
improved lens design for individual patients. Basic structural
attributes of the cornea are commonly assessed by pachymetry
and topography,406–408 while techniques such as the corneal
deformation to air pressure response provide the means to
assess dynamic corneal biomechanics in vivo.403,405,409,410
4. CONCLUSIONS
This report presents recommendations from International
Myopia Institute members on clinical trial protocols and
instrumentation to assess the efficacy of myopia control
treatments. A general consensus on study design was reached
regarding:
 The clinical trial protocol should adhere to the tenets of
the Declaration of Helsinki and be approved by the
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appropriate local ethics committee. Informed consent
should be written in a simple language and be acquired
from both guardians and children. An adverse event
reporting standard should be established. Clinical trials
should be registered on a recognized clinical trials
registry.
 Minimum length of a clinical trial is 3 years, with year 3
being without treatment (or with only control treatment)
to assess any rebound effect.
 Participant inclusion and exclusion criteria should be
clearly defined to include age, spherical equivalent
refractive error, astigmatism, anisometropia, and ocular
pathology. Participants with a history of any previous
myopia control treatment should be excluded.
 The included participants should be randomized into one
(or several) treatment group(s) and one control group.
Stratified randomization is useful to achieve age-matched
and level of refractive error-matched groups.
 The control group should receive a treatment that, as far
as possible, cannot be distinguished from the active
treatment, including the information provided and the
ocular health assessment conducted. Common control
treatments are single vision spectacles, monofocal soft
contact lenses, and a similar vehicle for pharmacological
interventions.
 The examiner collecting outcome data should always be
masked to the group-belonging of the participant.
Masking of the participant should be utilized whenever
possible.
The International Myopia Institute strongly recommends
using axial length as primary outcome measure of the efficacy
of myopia control treatments as well as refractive error when
applicable. Axial length should be assessed with an optical
biometric method, such as optical partial coherence interfer-
ometry that provides non-contact measurements with high
accuracy and precision. Refractive errors should be measured
objectively under cycloplegia with an open-field autorefractor
with a known measurement aperture that can be repeatedly
located close to the pupil center. The same type of cycloplegic
agent (preferably 1% tropicamide with optical treatments)
should be used throughout the clinical trial, and refraction
must not be measured before the maximal cycloplegic effect
has been achieved (an assessment of depth of cycloplegia
should be made before measurement). The refractive errors
should be expressed as mean spherical equivalent and
astigmatic power errors. To ensure accuracy, the same
instrumentation should be used throughout the time period
of the clinical trial and must be calibrated and validated using
an eye-model. The procedure should be carefully described to
allow for easy comparison, replication, and benchmarking.
Finally, when stating the reduction in axial elongation and
myopia progression between a treatment and a control group,
it is critical to report the time period over which the reduction
occurred. The meaningful treatment effect over 3 years (2
years treatment þ 1 year of no treatment to identify any
rebound effect) should be considered on a study-by-study basis
on factors identified in section 2.9 (see Fig. 1).
This report also provides an overview of secondary and
exploratory outcomes, which could be useful for future
instrumentation and treatment development (Table 5):
 Treatment and visit compliance is important for the
validity of the conclusion of a clinical trial. Electronic
reporting and reminders (e.g., via text messages) have
been shown to increase compliance.
 Participantive reporting on comfort and visual quality
during treatment is often assessed via questionnaires,
preferably electronic. Furthermore, for any participants
who discontinue treatment, the reason for discontinua-
tion should be documented.
 Binocular vision, heterophoria, and accommodative
function (at a minimum lag of accommodation and
consider accommodation facility) correlate with the
efficiency of the myopia control treatment and should
at least be assessed at baseline of the clinical trial.
 Several different modalities to measure visual function
exist. Participantive visual acuity should be determined
with logMAR charts. Additionally, contrast sensitivity,
reading speed, and glare estimation can provide more
detailed knowledge because they are more sensitive to
the quality of the retinal image.
 Peripheral refraction may be associated with myopia
progression and should be measured using a method such
as an open-field autorefractor validated for the purpose.
Preferably, head-turn should be used instead of eye-turn.
The most susceptible retinal area is not known, but as a
starting point it is recommended to assess the optical
errors 308 in the temporal visual field and also the
corresponding angle in the nasal visual field. Further out
in the periphery, measures of retinal shape may also
provide estimates of the peripheral refractive errors.
 Outdoor versus indoor activity is also associated with
myopia; outdoor activity early in life possibly protects
against onset of myopia, but with equivocal evidence for
progression. Environmental studies of children prior to
the ages typically associated with myopia onset might be
required, with new technologies to enable more com-
plete descriptions of the child’s visual environment.
Furthermore, differences in outdoor exposure may
interact with treatment effects, and the protocol of
clinical myopia control trials should be designed to
account for the influence of seasonal variation on the
estimated yearly progression of myopia.
 Give detailed assessments of the ocular biometry; for
instance, OCT is of special importance for some myopia
treatments. Pharmacological- or surgical-based myopia
control interventions should include posterior segment
imaging to assess any adverse effects to the posterior
segment. In OK, information on the anterior segment,
TABLE 5. Expected Minimum Data Set for Each Treatment Modality
Treatment
Modality
Distance
Visual
Acuity
Near
Visual
Acuity
Pupil
Size
Cycloplegic
Refraction
Axial
Length
Amplitude
of
Accommodation
Contrast
Sensitivity
Lens
Centration
Wearing
Time
Instillation
Compliance
Spectacles X X X X X X X — X —
Soft multifocal
contact lenses
X X X X X X X X X —
Orthokeratology X X X X X X X X X —
Pharmaceuticals X X X X X X X — — X
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especially corneal curvature and thickness, is essential,
but corneal tissue biomechanics is also important to
improve the lens design. Lens position and thickness may
also vary prior to and during myopia progression, and an
assessment of these at baseline and study end is
warranted.
Acknowledgments
The authors thank David S. Friedman, MD, Dana Center for
Preventive Ophthalmology Wilmer Eye Institute and Bloomberg
School of Public Health Senior Ophthalmologist, for his review of
the manuscript.
Supported by the International Myopia Institute. Publication
costs of the International Myopia Institute reports were
supported by donations from the Brien Holden Vision Institute,
Carl Zeiss Vision, Coopervision, Essilor, Alcon, and Vision Impact
Institute.
Disclosure: J.S. Wolffsohn, Alcon (F), Allergan (F), Aston EyeTech
(F, I), Atiya Vision (C), Bausch & Lomb (F), BetterVision Ltd (F),
British Contact Lens Association (C), CooperVision (F, C), Eaglet
Eye (F), European Union (F), Eyebag (F), EMPharma (F), EyeDocs
(F), Gelflex (F), Innovate UK (F), Johnson & Johnson Vision Care
(F, C, R), Lenstec (F), Medmont (F), Rayner (F), Santen (C, R), Shire
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